% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mandler:187170,
      author       = {Mandler, M. and Santic, Radmila and Gruber, Petra and
                      Cinar, Yeliz and Pichler, Dagmar and Funke, Susanne Aileen
                      and Willbold, Dieter and Schneeberger, Achim and Schmidt,
                      Walter and Mattner, Frank},
      title        = {{T}ailoring the {A}ntibody {R}esponse to {A}ggregated {A}ß
                      {U}sing {N}ovel {A}lzheimer-{V}accines},
      journal      = {PLoS one},
      volume       = {10},
      number       = {1},
      issn         = {1932-6203},
      address      = {Lawrence, Kan.},
      publisher    = {PLoS},
      reportid     = {FZJ-2015-00844},
      pages        = {e0115237 -},
      year         = {2015},
      abstract     = {Recent evidence suggests Alzheimer-Disease (AD) to be
                      driven by aggregated Aß. Capitalizing on the mechanism of
                      molecular mimicry and applying several selection layers, we
                      screened peptide libraries for moieties inducing antibodies
                      selectively reacting with Aß-aggregates. The technology
                      identified a pool of peptide candidates; two, AFFITOPES AD01
                      and AD02, were assessed as vaccination antigens and compared
                      to Aβ1-6, the targeted epitope. When conjugated to Keyhole
                      Limpet Hemocyanin (KLH) and adjuvanted with aluminum, all
                      three peptides induced Aß-targeting antibodies (Abs). In
                      contrast to Aß1-6, AD01- or AD02-induced Abs were
                      characterized by selectivity for aggregated forms of Aß and
                      absence of reactivity with related molecules such as Amyloid
                      Precursor Protein (APP)/ secreted APP-alpha (sAPPa).
                      Administration of AFFITOPE-vaccines to APP-transgenic mice
                      was found to reduce their cerebral amyloid burden, the
                      associated neuropathological alterations and to improve
                      their cognitive functions. Thus, the AFFITOME-technology
                      delivers vaccines capable of inducing a distinct Ab
                      response. Their features may be beneficial to AD-patients, a
                      hypothesis currently tested within a phase-II-study.},
      cin          = {ICS-6},
      ddc          = {500},
      cid          = {I:(DE-Juel1)ICS-6-20110106},
      pnm          = {553 - Physical Basis of Diseases (POF3-553)},
      pid          = {G:(DE-HGF)POF3-553},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000348562900006},
      doi          = {10.1371/journal.pone.0115237},
      url          = {https://juser.fz-juelich.de/record/187170},
}